Skip to Content

Cabaletta Bio Inc Ordinary Shares CABA

Morningstar Rating
$10.92 −0.29 (2.59%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CABA is trading at a 867% premium.
Price
$11.07
Fair Value
$61.66
Uncertainty
Extreme
1-Star Price
$287.87
5-Star Price
$3.79
Economic Moat
Zqdf
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CABA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$11.21
Day Range
$10.8811.50
52-Week Range
$9.0226.35
Bid/Ask
$10.50 / $12.00
Market Cap
$527.18 Mil
Volume/Avg
10 / 1.1 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
120

Comparables

Valuation

Metric
CABA
CRBU
VOR
Price/Earnings (Normalized)
Price/Book Value
2.570.820.89
Price/Sales
7.53
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
CABA
CRBU
VOR
Quick Ratio
12.4611.758.13
Current Ratio
12.6611.978.46
Interest Coverage
Quick Ratio
CABA
CRBU
VOR

Profitability

Metric
CABA
CRBU
VOR
Return on Assets (Normalized)
−33.60%−23.27%−48.29%
Return on Equity (Normalized)
−36.29%−28.24%−61.06%
Return on Invested Capital (Normalized)
−40.11%−26.03%−54.20%
Return on Assets
CABA
CRBU
VOR
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRLgrxvythTtl$595.6 Bil
VRTX
Vertex Pharmaceuticals IncJbnksbfqrVxsvyg$117.9 Bil
REGN
Regeneron Pharmaceuticals IncBpqhcktrrPxvfgt$108.5 Bil
MRNA
Moderna IncQnyvypkpLnl$63.9 Bil
BNTX
BioNTech SE ADRPqtcwjttFfx$23.4 Bil
ARGX
argenx SE ADRTgjhfjhJlwr$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncCpbssmycHghzvm$18.7 Bil
BMRN
Biomarin Pharmaceutical IncPjhgwkddSqzfbq$14.3 Bil
INCY
Incyte CorpCcyndymtKschrlw$12.9 Bil
UTHR
United Therapeutics CorpTdkfyvzrVfyp$12.1 Bil

Sponsor Center